DAPAGLIFLOZIN ADVISORY COMMITTEE MEETING

First Page		Document Content
Dapagliflozin Glycosides Hepatotoxicity Medicine Organochlorides Bristol-Myers Squibb		DAPAGLIFLOZIN ADVISORY COMMITTEE MEETING Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 22,98 KB Share Document on Facebook

	Att vara eller inte vara .... trender inom läkemedelsforskning Anders Ekblom Mölndal 2 December 2013 DocID: 1gs0F - View Document
	Forxiga, INN-dapagliflozin DocID: 1eAhO - View Document
	5.4 EMPAGLIFLOZIN, oral tablet, 10 mg, 25 mg, Jardiance®, Boehringer Ingelheim Pty Ltd Purpose of Application This submission seeks an Authority required listing for empagliflozin (Jardiance®) for the treatment of typ DocID: 17Ihe - View Document
	6.3 DAPAGLIFLOZIN, 10 mg tablet, Forxiga®, AstraZeneca Pty Ltd 1 Purpose of Application To request amendments to the current restriction for dapagliflozin for use in diabetes mellitus type 2 (T2DM) to provide prescribe DocID: 17FDZ - View Document
	Monthly briefings are produced in order to help members of the media and other interested people understand the work and advice of the Scottish Medicines Consortium. The detailed advice for each medicine that DocID: 177rO - View Document